Results 171 to 180 of about 2,972 (289)

Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment

open access: yes
American Journal of Hematology, EarlyView.
Ghulam Rehman Mohyuddin   +3 more
wiley   +1 more source

Desmopressin and bleeding risk in high-risk native kidney biopsy: updated meta-analysis of RCTs and observational studies. [PDF]

open access: yesRen Fail
Sartori Pacini G   +7 more
europepmc   +1 more source

Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sickle cell disease (SCD) is a chronic inflammatory state, characterized by increased plasma values of inflammatory and angiogenic proteins. Although red blood cell (RBC) transfusion is known to have immunomodulatory effects in other conditions, its potential effects on the inflammatory state in SCD remain largely unknown.
Lydian A. de Ligt   +9 more
wiley   +1 more source

Half-Dose versus Full Dose of Aprotinin in Cardiac Surgery: A Post-hoc Analysis of the Aprotinin European Registry. [PDF]

open access: yesEur J Cardiothorac Surg
Colson PH   +8 more
europepmc   +1 more source

Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML‐M4 and AML‐M5, Treated With Venetoclax Plus Azacitidine

open access: yes
American Journal of Hematology, EarlyView.
Marina Konopleva   +8 more
wiley   +1 more source

Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study

open access: yes
American Journal of Hematology, EarlyView.
Zhenbin Wei   +19 more
wiley   +1 more source

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong   +5 more
wiley   +1 more source

Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin (EPO) Due to EPO c.‐136 G>A Germline Mutation

open access: yesAmerican Journal of Hematology, EarlyView.
A novel erythropoietin (EPO) promoter mutation (c.‐136 G>A) causes autosomal dominant erythrocytosis via non‐renal expression of EPO. ABSTRACT We previously reported a five‐generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.‐136 G>A).
Lucie Lanikova   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy